A Subgroup Analysis of Clinical Efficacy Response and Quality of Life Outcomes from Phase 3 Study of Filgotinib in Patients with Inadequate Response to Biologic DMARDs Genovese, M., de Vlam, K., Gottenberg, J., Bartok, B., Tiamiyu, I., Guo, Y., Tasset, C., Sundy, J., Walker, D., Takeuchi, T., Kalunian, K. WILEY. 2019

View details for Web of Science ID 000507466900518